Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.5 (5'-nucleotidase)
 3,167 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Epidermal growth factor (EGF) is now well known as a potent mitogen and differentiation factor for a variety of cells both in vivo and in vitro. Like other polypeptide hormones, EGF initially binds to a specific plasma membrane receptor on the target cells. In this study, we investigated the effect of streptozotocin-induced diabetes on EGF receptors on rat liver plasma membranes. An apparent increase in serum glucose concentration was observed in diabetic rats, and treatment of diabetic animals with insulin normalized the glucose concentration to the control level. There was no marked difference in hepatic membrane markers among the control, diabetic and insulin-treated diabetic animals, as judged by protein, sialic acid contents, and phosphodiesterase I and 5'-nucleotidase activities. The binding of 125I-EGF to membranes was found to be significantly lower in diabetic than in control animals. The value in diabetic animals was about 55% of the control level. Insulin treatment of diabetic animals restored the binding of 125I-EGF to the control level, whereas triiodothyronine (T3) treatment had no effect. Scatchard analysis of the binding data clearly showed that the decrease in EGF binding was due to a decrease in the number of receptors rather than to a change in receptor affinity. The decrease in EGF receptor number in diabetic animals was also confirmed by an experiment on affinity labeling of EGF receptors. EGF stimulated the phosphorylation of hepatic EGF receptors (molecular weight = 170,000). The rates of basal and EGF-stimulated phosphorylation of the receptors were lower in diabetic than in control animals. Insulin treatment of diabetic animals restored the phosphorylation activity to control level, whereas T3 treatment had no apparent effect. There was no significant difference in serum EGF concentration among the control, diabetic and insulin-treated diabetic animals. These results indicate that insulin deficiency in vivo causes a decrease in hepatic EGF receptor number, and suggest that the actions of EGF on hepatocytes may also be affected by diabetes mellitus since the effects of EGF are receptor-mediated.
 ...
PMID:[Effect of experimental diabetes on epidermal growth factor (EGF) receptors in the rat liver]. 253 89

The ability of epidermal growth factor, insulin or guanosine thiotriphosphate to induce the release of two glycosyl-phosphatidylinositol-linked proteins from isolated human placental syncytiotrophoblast plasma membrane vesicles was investigated. Epidermal growth factor induced the ATP-dependent release of a fraction of syncytiotrophoblast plasma membrane placental alkaline phosphatase, whereas no release was detected following insulin treatment. This effect of epidermal growth factor was apparent at 30 min but not at 5 min. Guanosine thiotriphosphate stimulated the release of a small amount of syncytiotrophoblast plasma membrane placental alkaline phosphatase and appeared to have an additive effect when applied together with epidermal growth factor. Guanosine thiodiphosphate did not induce phosphatase release, but partially inhibited the epidermal growth factor response. 28.7% of syncytiotrophoblast plasma membrane 5'-nucleotidase was solubilized using glycosyl-phosphatidylinositol-specific phospholipase C. However, unlike placental alkaline phosphatase, no detectable release of 5'-nucleotidase was observed following treatment of syncytiotrophoblast plasma membrane vesicles with epidermal growth factor or guanosine thiotriphosphate. These results indicate (i) the presence of at least two placental alkaline phosphatase-releasing pathways in syncytiotrophoblast plasma membrane vesicles, and (ii) the presence of subpopulations of glycosyl-phosphatidylinositol-linked proteins sensitive to growth factor-induced release.
 ...
PMID:Growth factor-induced release of placental alkaline phosphatase from human syncytiotrophoblast membranes. 818 14